Published in
American Society of Hematology, Blood Advances, 19(4), p. 4924-4928, 2020
DOI: 10.1182/bloodadvances.2019001282
Links
Tools
Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement
Journal article published in 2020 by
Timothy Carll 
,
Anand Patel ,
Benjamin Derman ,
Elizabeth Hyjek,
Angela Lager ,
Pankhuri Wanjari ,
Jeremy Segal ,
Olatoyosi Odenike ,
Shiraz Fidai ,
Daniel Arber
,
Anand Patel ,
Benjamin Derman ,
Elizabeth Hyjek,
Angela Lager ,
Pankhuri Wanjari ,
Jeremy Segal ,
Olatoyosi Odenike ,
Shiraz Fidai ,
Daniel Arber
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Key Points Myeloid/lymphoid neoplasms with eosinophilia are driven by aberrant tyrosine kinases in pluripotent cells and display variable phenotypes. FGFR-driven hematolymphoid neoplasms are targetable by TKI inhibitors such as ponatinib; studies of specific FGFR inhibitors are ongoing.